H.R. 5333 - Over-The-Counter Monograph Safety, Innovation, and Reform Act of 2018
Health. 115th Congress (2017-2018) View bill details
- Sponsor:
- Robert E. Latta
- Summary:
- To amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes. (by CRS)
- Status:
- The bill was voted on in the House on July 15, 2018
House Vote: On Passage
by voice vote on July 16, 2018.
Other Votes:
Over-The-Counter Monograph Safety, Innovation, and Reform Act of 2018
H.R. 5333 — 115th Congress (2017–2018)
- Summary
- To amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes. (by CRS)
- Learn More
- At OpenCongress
- Title
- To amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes.
- Other Titles
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph User Fee Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph User Fee Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Over-the-Counter Monograph User Fee Act of 2018
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
- Sponsor
- Robert E. Latta
- Co-Sponsors
- Subjects
- Health
- Administrative law and regulatory procedures
- Drug safety, medical device, and laboratory regulation
- Government studies and investigations
- Inflation and prices
- Prescription drugs
- User charges and fees
- Related Bills
- Major Actions
Introduced 3/19/2018 House 7/16/2018 - Bill History
-
Chamber/Committee Motion Date Result currently selected House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. 7/16/2018 by voice vote Action Date Description Introduced 3/19/2018 3/19/2018 Introduced in House 3/19/2018 Referred to the House Committee on Energy and Commerce. 3/23/2018 Referred to the Subcommittee on Health. 5/09/2018 Committee Consideration and Mark-up Session Held. Put on a legislative calendar 5/09/2018 Ordered to be Reported (Amended) by Voice Vote. 7/16/2018 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-827. Put on a legislative calendar 7/16/2018 Placed on the Union Calendar, Calendar No. 640. 7/16/2018 Mr. Latta moved to suspend the rules and pass the bill, as amended. 7/16/2018 Considered under suspension of the rules. 7/16/2018 DEBATE - The House proceeded with forty minutes of debate on H.R. 5333. currently selected House Vote on Passage 7/16/2018 On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. 7/16/2018 Motion to reconsider laid on the table Agreed to without objection. Put on a legislative calendar 7/17/2018 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 518. Number Sponsor Date Offered Status
MapLight did not identify any interest groups that took a position on this vote.
You may be able to explore campaign contributions data if you add interest groups.
Includes reported contributions to congressional campaigns of House members in office on day of vote, from interest groups invested in the vote according to MapLight, November 29, 2014 – November 28, 2016.
Contributions data source: OpenSecrets.org
Contributions data source: OpenSecrets.org
